Niacin (Vitamin B3)

Niacin (Vitamin B3)

Once the most prescribed lipid drug in America — now largely forgotten in the statin era. But niacin is also a potent NAD+ booster, a GPR109A activator with anti-inflammatory effects, and the only agent that lowers lipoprotein(a). David Sinclair's lab studies it. Peter Attia questions whether we abandoned it too soon. Here's what the evidence actually shows.

Evidence Tier: 🥈 Silver — Strong lipid-modifying effects but cardiovascular outcomes data is mixed; NAD+ precursor role promising but longevity data is preclinical.

⚖️ At a Glance: Pros & Cons

What Is Niacin (Vitamin B3)?

Niacin is one of the eight B vitamins. It exists in two main forms: nicotinic acid (the form that causes flushing and is used for cholesterol) and nicotinamide (the non-flushing form used in skincare and some supplements). Both are precursors to NAD+ (nicotinamide adenine dinucleotide), a coenzyme essential for energy production in every cell of your body.

The body can also make niacin from the amino acid tryptophan — but inefficiently. About 60 mg of tryptophan yields 1 mg of niacin. This is why severe niacin deficiency (pellagra) occurs in populations relying heavily on corn-based diets, since corn protein is low in tryptophan.

In the 1950s, researchers discovered that high-dose nicotinic acid — far beyond what's needed to prevent deficiency — dramatically improved cholesterol profiles. This launched niacin's career as arguably the first "lifestyle drug": a vitamin used at pharmaceutical doses to treat a chronic condition.

How It Works

Niacin works through multiple mechanisms — some well understood, others still being worked out:

1. Lipid effects (via GPR109A in fat tissue): Niacin binds to the GPR109A receptor on fat cells, which suppresses the breakdown of triglycerides into free fatty acids. With fewer free fatty acids reaching the liver, the liver produces less VLDL (the precursor to LDL). This cascade lowers LDL, triglycerides, and lipoprotein(a) while raising HDL. The HDL-raising effect is particularly strong because niacin also slows HDL clearance from the blood.

2. The flush (also GPR109A): The same GPR109A receptor exists in skin immune cells called Langerhans cells. When niacin activates these, they release prostaglandin D2, which dilates blood vessels in the skin — causing the notorious "niacin flush." This is uncomfortable but not dangerous. The flushing response actually blunts over time with continued use.

3. NAD+ biosynthesis (Preiss-Handler pathway): Nicotinic acid is converted to NAD+ through a three-step pathway (Preiss-Handler) that is distinct from the pathway used by nicotinamide and nicotinamide riboside. This means niacin provides an alternative route to boost NAD+ — one that may bypass bottlenecks in the other pathways that develop with age.

4. Anti-inflammatory effects (GPR109A on immune cells): Beyond fat and skin, GPR109A is also expressed on macrophages and other immune cells. Activation here suppresses inflammatory signaling — an effect that may contribute to cardiovascular protection independent of the lipid changes. Recent 2026 research showed niacin promotes motor recovery after spinal cord injury through exactly this Hcar2/GPR109A-dependent anti-inflammatory mechanism (PMID: 42068080).

The Longevity Connection

🥈 Cardiovascular Protection (Silver-tier evidence)

This is where niacin has the most data — and also the most controversy. The Coronary Drug Project (1975), one of the earliest large cardiovascular outcomes trials, showed niacin reduced nonfatal myocardial infarction by 27% compared to placebo. A 15-year follow-up found a significant 11% reduction in all-cause mortality in the niacin group — long after the trial had ended and most participants had stopped taking it.

But the modern trials tell a different story. AIM-HIGH (2011, PMID: 22085343) tested niacin added to statin therapy in 3,414 patients with established cardiovascular disease. Despite raising HDL by 25% and lowering triglycerides, niacin showed no additional benefit over statin alone. The trial was stopped early for futility.

HPS2-THRIVE (2014, PMID: 25014686), an even larger trial of 25,673 patients, tested extended-release niacin plus laropiprant (an anti-flushing drug) on top of statin therapy. Again, no cardiovascular benefit — but there were significant increases in adverse events: new-onset diabetes, infections, and bleeding.

A 2010 meta-analysis of 11 trials (PMID: 20079494) found niacin reduced major coronary events by 25% and stroke by 26% — but this was driven largely by the pre-statin era studies. A 2019 meta-analysis (PMID: 30861690) of HDL-targeting treatments (niacin, fibrates, CETP inhibitors) across 31 trials confirmed no cardiovascular benefit from raising HDL.

Our interpretation: Niacin clearly improves lipid profiles. But in the statin era — when LDL is already aggressively lowered — the incremental benefit of further HDL-raising appears to be zero. The question is whether niacin has value in people who cannot take statins, or in specific high-risk subgroups (elevated Lp(a), low HDL, high triglycerides). This remains unanswered.

🥉 NAD+ Boosting (Bronze-tier, preclinical)

Niacin is an NAD+ precursor, and NAD+ levels decline with age. This is the basis for interest in niacin as a longevity supplement — separate from its lipid effects. The Preiss-Handler pathway that converts niacin to NAD+ involves the enzyme NAPRT, which is expressed in most tissues.

However, there are no clinical trials testing niacin specifically for longevity outcomes or NAD+ restoration in aging humans. The NAD+ precursor trials that exist use nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), not nicotinic acid. Niacin at pharmacological doses (500-2000 mg) delivers far more NAD+ precursor than typical NR/NMN doses — but also comes with the flushing and metabolic side effects that NR/NMN avoid.

🥉 Kidney Protection (Bronze-tier, observational)

A 2026 study in CKD patients (PMID: 42579537) examined renal outcomes of triglyceride-targeting therapies including niacin. The evidence for kidney protection is suggestive but not definitive — observational data shows associations, but randomized trials specifically in CKD are lacking.

🥉 Neurological Applications (Bronze-tier, emerging)

A 2023 review in Neurotherapeutics (PMID: 37084148) catalogued promising neurological applications for niacin, including potential roles in Parkinson's disease, multiple sclerosis, and traumatic brain injury. The mechanisms involve NAD+ replenishment, anti-inflammatory GPR109A signaling, and improved mitochondrial function. All of this is preliminary — clinical trials in neurological conditions are just beginning.

Key Studies

Dosing and Safety

Recommended Forms and Doses

Dosing Protocol (for lipid management under medical supervision)

1. Start low: 100-250 mg immediate-release niacin with food at bedtime
2. Titrate slowly: Increase by 250 mg every 2-4 weeks as tolerated
3. Target: 1000-2000 mg/day for lipid effects (most trials used 1500-2000 mg)
4. Take with food to reduce flushing intensity
5. Aspirin pretreatment: 325 mg aspirin 30 minutes before niacin reduces flushing by ~30-40% (blocks prostaglandin production)
6. Avoid alcohol and hot drinks around dosing — both worsen flushing

Side Effects

❓ Common Questions About Niacin

The Bottom Line

Niacin is a fascinating molecule that sits at the intersection of three domains: it's a vitamin, a lipid drug, and an NAD+ precursor. It improves every number on a standard lipid panel. It's the only oral agent that lowers lipoprotein(a). It's a cheap, generic, well-studied compound with decades of safety data.

And yet, in the statin era, two massive trials found it added nothing when LDL was already well-controlled. The HDL-raising strategy — raise the "good cholesterol" and patients will do better — simply did not pan out. This doesn't mean niacin is useless. It means the context matters enormously.

Our verdict: Niacin is not a first-line longevity supplement. If your goal is NAD+ boosting, nicotinamide riboside or NMN provide the same benefit without the flushing and metabolic side effects. If your goal is cardiovascular protection and you're already on a statin with good LDL control, the evidence says niacin adds nothing.

Who might still benefit: People who cannot tolerate statins, those with isolated low HDL and elevated Lp(a) not addressed by other therapies, and those specifically targeting the GPR109A anti-inflammatory pathway (recognizing this evidence is preclinical). At lower doses (250-500 mg/day), niacin is an inexpensive NAD+ precursor worth considering — but the longevity evidence for this dose is entirely indirect.

If you choose to take it: Use immediate-release niacin, start at 100-250 mg with food and aspirin, titrate slowly, monitor liver enzymes and glucose, and avoid sustained-release formulations entirely. And talk to your doctor.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Niacin at pharmacological doses is a drug-level intervention with real risks including hepatotoxicity and glucose dysregulation. Always consult your physician before starting, stopping, or changing any medication or supplement regimen. My Longevity Edge is a research curation service, not a medical practice.

Sources

1. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231(4):360-381. (15-year follow-up: Canner PL et al., J Am Coll Cardiol. 1986;8(6):1245-1255)
2. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267. PMID: 22085343
3. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-212. PMID: 25014686
4. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210(2):353-361. PMID: 20079494
5. Riaz H et al. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2019;26(5):533-543. PMID: 30861690
6. Rajkumar S et al. Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD. Clin J Am Soc Nephrol. 2026. PMID: 42579537
7. Gasperi V et al. The Promise of Niacin in Neurology. Neurotherapeutics. 2023;20(4):1037-1054. PMID: 37084148
8. Zhang Y et al. Niacin promotes motor function recovery after spinal cord injury via Hcar2-dependent microglia immunometabolic regulation. Clin Transl Med. 2026. PMID: 42068080
9. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101(8A):20B-26B. PMID: 18375237
10. Lukasova M et al. Nicotinic acid (niacin): new lipid-independent mechanisms of action. Curr Atheroscler Rep. 2013;15(3):311. (GPR109A review)
11. Chen AC et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618-1626. (Nicotinamide for skin cancer — note: different form than nicotinic acid)